Isle of Man opticians to treat more eye conditions
Opticians have traditionally provided only eye tests and supplied glasses funded by the NHS.
Convenience
The new system will see that expanded to include extra eye examinations including paediatric reviews and treatment for a range of other conditions.It will also allow for follow-up and repeat procedures previously offered at hospital clinics, as well as post-operative cataract examinations and cataract referral advice and counselling.High street opticians will also be able to cater for unscheduled appointments and urgent care for conditions including the sudden onset of blurred vision, eye pain, eye infections and the gradual loss of vision.Manx Care said those services that had previously been offered by GPs or at the hospital would remain free of charge.The changes follow on from a pilot Minor Eye Conditions Service carried out in recent years at Specsavers outlets on the island, offering an alternative to going to a doctor for some eye conditions.That scheme will now be superseded by the broader roll-out of services across the community by all island opticians.However, Manx Care said in the case of more serous eye conditions - including severe pain or sudden vision loss – patients should still attend Noble's Hospital's Accident and Emergency Department.
Read more stories from the Isle of Man on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC Isle of Man on Facebook and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
15 minutes ago
- Times
Junior doctors strikes: NHS staff absence due to walkouts falls
NHS staff absences due to industrial action fell by 7.5 per cent compared with the last round of junior doctors' strikes, with 1,243 fewer staff absent during the most recent walkout. The analysis from the health service also found that more care was delivered during the five-day strike than in previous industrial action. Junior doctors, now known as resident doctors in the NHS, walked out for five days on July 25 in a dispute with the government over pay. Wes Streeting, the health secretary, and the British Medical Association (BMA) say they are continuing talks over the summer to prevent further strike action from the doctors. The NHS estimated that 11,071 more appointments and procedures went ahead as planned compared with industrial action from junior doctors in 2024. In previous industrial action, hospitals cancelled or rescheduled elective procedures to prepare for the walkouts. However, during this round of strikes, hospitals endeavoured to keep planned appointments going ahead as scheduled throughout the walk-outs. Streeting said the figures show the NHS 'was more resilient against last month's strike action than ever before'. 'We are getting on with the job of delivering progress in the face of strike action, and we will continue to put patients first,' he said. 'I had a constructive conversation with the BMA last week and I am glad they've agreed to continue engagement through the summer with the mutual aim of preventing further disruption to the NHS and patients.' Professor Meghana Pandit, NHS national medical director, said: 'It is very welcome news that the resident doctors committee has returned to talks, and we hope this leads to a resolution that avoids further disruption for patients.' Daniel Elkeles, chief executive of NHS Providers, which represents hospital trusts, said: 'Despite a five-day strike in July by some doctors, the NHS provided an estimated 11,000 more appointments and procedures compared to during their five-day walkout in July last year.' • NHS patients told to brace for strikes until Christmas and beyond 'We hope that talks between the union and the government bear fruit and that any more disruptive strikes can be avoided. NHS trust leaders want to focus on improving services for patients and doing everything they can to improve things for valued resident doctors.' The doctors' union has, however, said that the action 'was totally avoidable'. It has previously said that the difference in absences could not be accurately compared between the strike years due to changes in the numbers taking annual leave. A spokesman added: 'Had the government just come forward with a credible offer toward pay restoration for resident doctors, those doctors would have been at work. Instead, government inaction meant we saw yet more cancellations, delays and chaos in a health system that is already seeing far too much of all three. 'We hope government uses the opportunity of our ongoing talks to avoid any need for future action. Today's figures show there are far too many patients on waiting lists relying on a swift and just resolution to this dispute.' Separate NHS figures show that the health service delivered a record number of appointments in June, with 103,563 more treatments carried out than this time last year. The latest performance data from NHS England shows an estimated 7.37 million treatments were waiting to be carried out at the end of June, relating to 6.23 million patients — up from 7.36 million treatments and just under 6.23 million patients at the end of May. The slight increase, which NHS officials have put down to more people coming forward for appointments, comes after the list fell for two consecutive months. The numbers waiting for more than 18 months to start treatment were also down to 1,103, from 1,237 in May. Some 10,517 patients had been waiting more than 65 weeks, down from 11,522 the previous month. This figure stood at 58,024 in June 2024. The number of patients waiting more than 52 weeks to start routine treatment also fell to 191,813 from 196,920 at the end of May. Tim Gardner, assistant director of policy at the Health Foundation, said: 'While summer is often a time for the NHS to catch its breath, today's data shows hospitals and ambulance services remain under relentless pressure.'
Glasgow Times
34 minutes ago
- Glasgow Times
Mounjaro prices double as weight loss jab popularity soars
US-based Eli Lilly says a 5mg dose will nearly double from £92 to £180 from September 1, while a 15mg pen will rise from £122 to £330. A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access." READ NEXT: Mounjaro could be available on prescription by Glasgow health board READ NEXT: Cumbernauld woman's surgery goal after Mounjaro weight loss The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability." More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Recommended reading: Mounjaro warning as pens ruined by heatwave temperatures This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave. Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal. 'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.' 8 tips to protect Mounjaro and other weight-loss injections during hot weather Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces. Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective. 'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."
BBC News
an hour ago
- BBC News
Cost of weight loss drug Mounjaro may rise significantly
People paying privately for weight-loss drug Mounjaro in the UK face a rise in the cost of the treatment after manufacturer Eli Lilly said it was increasing the list price of the drug by as much as 170%.It means the suggested price for a month's supply of the highest dose of the drug will rise from £122 to £330, although the rise for lower doses will be smaller. More generally, retailers who sell the drug may be able to negotiate discounts to the list price, so it is possible the impact on consumers will be announcement does not affect the price the NHS pays, as the service has negotiated a heavily-discounted rate for those getting the drug on prescription. The weekly injection works by making you feel full so you eat less, and can help people lose 20% of their body there are thought to be around 1.5 million people on weight loss drugs in the UK with more than half of them on Mounjaro. Estimates suggest nine in 10 pay for these drugs privately, buying from online services and high street Lilly said the drug had been sold in the UK at a price that was "significantly below" that charged in other European countries. Trump threat It comes after US President Donald Trump complained about the high cost of drugs in the has threatened the pharmaceutical industry with a "most favoured nation" drug pricing proposal to peg US prices to those Lilly said it agreed with the objective expressed by President Trump that costs should be shared more fairly – although a "most favoured nation" approach was not the right suggests prices in the US can be three times higher than in other rich a statement, Eli Lilly said: "The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited availability."At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability."With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation."Dr Leyla Hannbeck, head of the Independent Pharmacies Association, said she was "shocked and very disappointed" by the price rise."This is a real blow to patients, at a time when more and more people worried about their weight are turning to jabs. "It is vital that patients who are already taking Mounjaro talk to their local pharmacy before they take any action."Those patients considering weight-loss jabs should also not be put off as Mounjaro is not the only option - local pharmacies are best placed to offer vital advice about the range of treatments available."She said it was important other weight loss drug manufacturers hold their nerve and their prices - alongside Mourjaro Novo Nordisk drug Wegovy is widely used in the UK."The British market for weight-loss jabs will is only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient."
